2月10日，中国物流与采购联合会发布的数据显示，2025年全国社会物流总额368.2万亿元，按可比价格 计算，同比增长5.1%，全年社会物流运行保持平稳态势。其中，2025年一、二、三、四季度全国社会 物流总额分别增长5.7%、5.5%、5.2%、5.0%，全年各季度物流需求增速保持稳定增长，物流对实体经 济的拉动作用强劲。 中国物流信息中心表示，2025年物流需求规模稳步扩张、结构优化的同时，物流供给主动适配新质生产 力发展与产业转型等升级需求，推动经济运行中的物流效率持续改善，社会物流总费用与GDP比率降至 历史最低水平，物流对经济发展的支撑效能不断增强。 "进口物流稳定恢复为缓解国际局势的不确定性影响、助力产业链平稳运转提供了坚实支撑。"中国物流 信息中心表示。 新质生产力不断发展壮大，全链条物流需求逐步成型。"新质生产力相关物流需求围绕产业链上下游逐 步形成紧密的循环带动格局。"中国物流信息中心表示，新兴产业物流需求增速显著，2025年工业机器 人物流量同比增长28%，新能源汽车物流量同比增长25.1%。 物流相关基础设施投资保持稳定 2025年，全国社会物流总费用19.5万亿元，同比增长3.0%，年 ...

牛证街货重货区在26200-26299区间，该区间最新牛证数量为1474张，较上一交易日减少361张；牛证街货最多新增在26800-26899区间，该区 间最新牛证数量为780张，较上一交易日增加593张。 | 牛證街貨 | | - 恒指牛熊證期指張數比例 - | | | 熊證街貨 | | --- | --- | --- | --- | --- | --- | | 70.28% | | | | | 29.72% | | (14,881張) | | (以相對期指張數計算) | | | (6,292張) | | 指數區域 | 相對期指張數[括號內為一日變化] | | | 信證精選 | 實際槓桿 | | 28,200 - 28,299 | 445(+80) | | | 60466 院 | 23.6 | | 28,100 - 28,199 | 750(+53) | | 車覧品 | 61721 熊 | 25.9 | | 28.000 - 28.099 | 158(+102) | | | 53605 HE | 28.3 | | 27,900 - 27,999 | 170(+56) | | | 64737 熊 | 31.2 ...

【美元指数】衡量美元对六种主要货币的美元指数当天下跌0.02%，在汇市尾市收于96.799。截至纽约 汇市尾市，1欧元兑换1.1894美元，低于前一交易日的1.1921美元；1英镑兑换1.3666美元，低于前一交 易日的1.3699美元。1美元兑换154.49日元，低于前一交易日的155.68日元；1美元兑换0.7682瑞士法郎， 高于前一交易日的0.7660瑞士法郎；1美元兑换1.3551加元，低于前一交易日的1.3557加元；1美元兑换 8.9021瑞典克朗，低于前一交易日的8.9094瑞典克朗。 周二，三大指数涨跌不一，道指最高上涨至50512.79点，再创盘中历史新高。最新零售销售报告显示12 月消费者支出持平，低于经济学家预期的0.4%月度增幅。11月零售销售增长0.6%。投资者等待将于周 三发布的1月非农就业报告。 【贵金属】现货黄金跌0.74%，报5022.97美元；现货白银报80.818美元/盎司。富国银行表示，近期黄金 价格的回调是此前大幅上涨后的健康修正。现货黄金价格较1月底创下的纪录高点下跌超过10%，主要 原因是金价较200日均线上涨超过30%后出现获利回吐。该行将2026年黄金目标价 ...

ATLANTA--(BUSINESS WIRE)--PulteGroup, Inc. (NYSE: PHM) ("PulteGroup†) announced today the pricing of an underwritten public offering of $800 million in aggregate principal amount of its senior unsecured notes, consisting of $400 million aggregate principal amount of 4.250% senior notes due March 1, 2031 and $400 million aggregate principal amount of 4.900% senior notes due March 1, 2036. The senior notes due 2031 were offered to the public at 99.658% of the principal amount and have a yield to. ...

黄金前景也受到各大央行持续购金的支撑，包括波兰上月宣布将再购入 150 吨黄金，波兰是去年最大的 黄金买家。他还补充说，黄金 ETF 的资金流入也保持稳定，仅在上周的调整期间出现短暂下降后便回 升。 智通财经APP获悉，法国巴黎银行大宗商品策略总监 David Wilson 表示，到今年年底，黄金价格可能会 攀升至每盎司 6000 美元，随着宏观经济和地缘政治风险的持续存在，金银比价也将上升。Wilson 表 示，虽然金银比价仍低于 80 年代的两年平均水平，但已经反弹。 他表示："我认为两者之间仍然存在进一步脱节的空间。对我来说，黄金的优势在于它能提供白银无法 提供的那种风险保护。" 包括德意志银行和高盛在内的许多银行和资产管理公司都看好黄金价格，认为其将因这些长期需求驱动 因素而复苏。为了凸显官方需求的强劲势头，中国央行在 1 月份将黄金购买计划延长至第 15 个月。 与此同时，受亚洲地区强劲的实物白银买盘推动，白银价格在过去几个月经历了剧烈波动。然而，随着 金属供应流入欧洲和亚洲，实物白银市场目前已出现疲软迹象。Wilson 认为，即将到来的农历新年假 期可能会进一步抑制中国对白银的需求。 ...

Financial Data and Key Metrics Changes - The company reported Q4 2025 revenue of nearly $490 million, marking an 18% year-over-year increase and a 6% sequential increase, which was at the high end of guidance [4][12] - For the full year 2025, total revenue grew over 20% to $1.8 billion, with earnings per share increasing by over 70% to $6.41 [4][16] - Gross margin for Q4 was 39.7%, up 60 basis points sequentially, and for the full year, gross margin improved 240 basis points to 38.7% [12][16] - Operating cash flow reached a record $235 million for the year, with Q4 cash flow from operations at $80 million [12][16] Business Line Data and Key Metrics Changes - Data center computing revenue more than doubled year-on-year to $587 million, with Q4 revenue reaching a record $178 million, up 101% year-over-year [5][13][16] - Semiconductor revenue grew 6% year-on-year to $840 million, marking the second-highest level in company history [5][16] - Industrial and medical revenue decreased 11% for the full year but showed signs of recovery with a 10% sequential increase in Q4, returning to year-over-year growth for the first time in two years [5][13][16] Market Data and Key Metrics Changes - The company expects data center revenue to grow more than 30% in 2026, driven by strong demand from hyperscalers [10][19] - Semiconductor market forecasts indicate a strong second half of 2026, supported by increased customer demand and investments in advanced logic and memory capacity [10][19] - The industrial and medical market is expected to continue improving, with growth anticipated over the next few quarters as inventory levels normalize [10][19] Company Strategy and Development Direction - The company is focused on a diversification strategy across multiple high-value markets, which has allowed it to deliver consistent financial results [11][21] - Continued investment in R&D and marketing has built a strong portfolio of new products and a healthy design win pipeline [11][21] - The company is expanding manufacturing capacity in the Philippines, Mexico, and Thailand to support growth, with the Thailand factory expected to generate over $1 billion in annual revenue capacity once fully operational [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for growth, citing strong demand trends across all target markets entering 2026 [10][19] - The company anticipates that gross margins will exceed 40% in 2026, driven by improved manufacturing efficiency and a favorable product mix [9][19] - Management noted that while supply chain constraints may impact growth, they are proactively building inventory to mitigate risks [33][50] Other Important Information - The company launched 26 new products in 2025, contributing to revenue growth and customer engagement [6][11] - The company is actively pursuing acquisition opportunities to expand its technology portfolio, particularly in the industrial and medical sectors [11][65] Q&A Session Summary Question: How does the company view semiconductor capital growth in relation to industry expectations? - Management believes the company is well-positioned for structural share gains in semiconductor markets due to broad acceptance of new technologies [24][25] Question: What is the outlook for data center growth and customer demand? - The company expects over 30% growth in data center revenue, primarily based on existing customer demand, with additional upside potential from new customers [27][28] Question: What are the constraints affecting growth in the semiconductor sector? - Supply chain issues, particularly related to processors and memory, may limit growth, but the company is taking steps to build strategic inventory [33][50] Question: How does the company plan to manage operating expenses with the new Thailand facility? - Operating expenses are expected to grow but will be managed within the projected growth framework, with investments in Thailand accounted for in the overall strategy [76][78]

Financial Data and Key Metrics Changes - Gilead reported total product sales of $28.9 billion for 2025, a 1% increase from 2024, exceeding guidance due to strong HIV sales growth despite a $1.1 billion headwind from Medicare Part D redesign and a $900 million decline in Veklury revenue [33][34] - The base business revenue, excluding Veklury, was $28 billion, up 4% from 2024, also surpassing guidance [33] - Non-GAAP diluted EPS for 2025 was $8.15, in line with guidance, reflecting lower R&D expenses and higher revenues [36] Business Line Data and Key Metrics Changes - The HIV business grew 6% year-over-year to $20.8 billion, driven by strong demand for Biktarvy and Descovy, with Biktarvy sales reaching $14.3 billion, up 7% [34][11] - The liver business also grew 6% to $3.2 billion, primarily due to the strong performance of Livdelzi [34][17] - Oncology product Trodelvy saw a 6% increase in sales to $1.4 billion, driven by demand in metastatic breast cancer treatment [34][18] - Cell therapy sales declined 7% year-over-year to $1.8 billion, reflecting competitive pressures [34][20] Market Data and Key Metrics Changes - The HIV prevention portfolio, including Yes2Go, grew significantly, with fourth-quarter sales of Yes2Go at $96 million and full-year sales at $150 million [13][15] - The U.S. market for HIV prevention is expanding, with Descovy achieving over 45% market share [13] - Livdelzi's market share in the U.S. for second-line primary biliary cholangitis exceeded 50% [17] Company Strategy and Development Direction - Gilead is targeting four commercial launches in 2026, including Trodelvy for first-line metastatic triple-negative breast cancer and a new daily oral combination for HIV treatment [6][22] - The company aims to maintain expense discipline while investing in new product launches and expanding its pipeline, with up to 10 ongoing and potential new launches through 2027 [7][8] - Gilead's strategy focuses on diversifying its portfolio and enhancing its clinical pipeline, which is considered the strongest in its history [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with a strong position, citing no major product losses expected until 2036 and a commitment to returning capital to shareholders [8][43] - The company anticipates a 2% headwind to growth in 2026 due to drug pricing agreements and changes to the Affordable Care Act, but expects underlying growth of 6% absent these factors [41][42] - Management highlighted the importance of ongoing clinical trials and product launches in driving future growth [24][32] Other Important Information - Gilead returned $5.9 billion to shareholders in 2025, including $1.9 billion in share repurchases [42] - The company plans to invest approximately $1 billion annually in early-stage pipeline development and partnerships [43] Q&A Session Summary Question: Can you elaborate on the assumptions driving the $800 million guidance for Yes2Go? - Management highlighted strong access with 90% payer coverage and ongoing direct-to-consumer campaigns to increase awareness and drive growth [45][48] Question: What type of share gains do you expect for Anito-cel in the fourth-line setting? - Management expects modest contributions in 2026 post-launch, with a goal to become the market leader over time due to its efficacy and safety profile [52][56] Question: Are you expecting cannibalization of Descovy PrEP sales by Yes2Go? - Management anticipates that while Yes2Go will grow, Descovy will also continue to perform well in 2026, with both products benefiting from increased awareness in HIV prevention [58][60] Question: Can you discuss the profile of the long-acting 6-month treatment drug GS-3242? - Management expressed excitement about GS-3242's potential, emphasizing its differentiated profile and the importance of its combination with lenacapavir [63][66] Question: What do you need to show in the PURPOSE 365 study for lenacapavir for PrEP? - The study aims to demonstrate effective prevention through pharmacokinetics and safety, with potential market expansion opportunities if successful [69][73]

Financial Data and Key Metrics Changes - Total ARR grew by 3% on a reported basis and 1% in constant currency, marking a stabilization milestone for the business [15][16] - Fourth quarter total revenue was $421 million, up 3% year-over-year as reported and 1% in constant currency, exceeding expectations [16][17] - Free cash flow for the full year reached $285 million, surpassing the high end of the outlook [15][19] - Non-GAAP diluted earnings per share were $0.74, exceeding the top end of the outlook range by $0.17 [18] Business Line Data and Key Metrics Changes - Cloud ARR grew by 15% as reported and 13% in constant currency, now representing 46% of total ARR [16] - Consulting services revenue for the fourth quarter was $53 million, down 4% year-over-year as reported and down 6% in constant currency [17] Market Data and Key Metrics Changes - Customer engagement across all regions and industries shifted towards AI and Elastic Compute, indicating a growing interest in AI solutions [6][12] - The company saw a resurgence of interest in its hybrid model, with customers leveraging both on-prem and cloud deployment options [5][21] Company Strategy and Development Direction - The company is focused on harnessing Agentic AI systems to enable autonomous decision-making at enterprise scale [5] - A strong emphasis is placed on product development and innovation, with plans to invest more resources in this area to fuel future growth [15][26] - The company aims to maintain a hybrid deployment strategy to meet diverse customer needs driven by data sovereignty and regulatory environments [5][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 on solid footing, with expectations for continued growth in total ARR, operating margin, and free cash flow [15][23] - The company anticipates typical seasonality in ARR, with Q1 expected to be the largest renewal and highest erosion quarter [20][23] Other Important Information - The company announced a board refreshment initiative, with plans to add new independent directors to enhance governance [27] - A new partnership with Unstructured.io was established to automate the ingestion of unstructured content into analysis-ready data [10] Q&A Session Summary Question: On-premise AI materiality and customer investment - Management sees on-premise AI as a key growth driver, with increased POC activity leading to production deployments [30] Question: Free cash flow growth versus EPS guidance - The difference in guidance is attributed to a one-time tax benefit in Q4, affecting EPS but not free cash flow [32][33] Question: Drivers behind growth inflection - The AI marketplace is opening new opportunities, with improved retention rates and product announcements contributing to growth [36][38] Question: Visibility on migration versus expansion - Migration deals are complex and timing is hard to gauge, while expansions provide more consistent revenue growth [40][41] Question: Impact of new AI-related solutions on revenue - New product capabilities are expected to contribute to growth, but not heavily factored into current financial outlook [62] Question: Investments in headcount and sales hiring - The company plans to invest in forward-deployed engineering and product development to enhance AI solutions [68][70] Question: Seasonality and revenue growth expectations - Typical seasonality is expected, with Q1 showing erosion followed by growth in subsequent quarters [73][75] Question: Board refreshment and governance changes - The board refreshment process is ongoing, with a focus on enhancing skill mix and governance [77] Question: Characteristics of successful software companies in AI transition - The company emphasizes its role as a data layer for AI, positioning itself for growth in the autonomous AI space [81][82] Question: Operating margin expansion drivers - Expansion will be driven by gross margin improvements and efficiencies in operating expenses [84]

Hoyle Pond1S Zone: High-grade intersections confirm potential to extend zone to depth, to the east and west2 59.18 gpt over 6.2m, including 488.00 gpt over 0.70 m31.33 gpt over 1.6m28.73 gpt over 5.1m69.34 gpt over 4.1m TVZ: Encouraging results from infill drilling north of main target zone3 4.10 gpt over 30.1m, including 6.65 gpt over 4.3m, and including 7.32 gpt over 6.0m, 5.37 gpt over 1.6m and 3.9 gpt over 7.5m. Owl Creek: New drilling 3 km west of Hoyle Pond confirms and expands mineralization betwee ...

VANCOUVER, British Columbia, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) reported Adjusted EBITDA of negative $6.2 million in the fourth quarter of 2025. In comparison, the Company reported Adjusted EBITDA of $14.4 million in the fourth quarter of 2024 and Adjusted EBITDA of negative $65.9 million in the third quarter of 2025, which included a non-cash export tax expense of $59.5 million related to the determination of final duty rates from the sixt ...